Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
mRNA export factor RAE1 (RAE1)
- Target
- RAE1
- Molecular classification
- Other (mRNA export factor), mRNA binding protein, WD40 repeat-containing protein
01
Overview
mRNA export factor RAE1 (RAE1) is a conserved WD40 repeat-containing protein involved in nuclear export of mRNA and mitotic spindle checkpoint regulation[1][2][4][5][3]. RAE1 interacts with NUP98 via the Glebs motif, forming a complex essential for mRNA transit through the nuclear pore complex and for RNA binding[2][3]. In humans, RAE1 also participates in mitotic spindle formation, epithelial-mesenchymal transition (EMT), and maintenance of chromosome stability[1][4][5]. Haploinsufficiency or dysregulation can contribute to aneuploidy, aging phenotypes, neurodevelopmental syndromes, and is linked to tumor aggressiveness—particularly in breast cancer[1][5]. Rae1/Nup98 can be targeted by certain viral proteins to inhibit host mRNA export[2]. There are currently no therapeutics directly targeting Rae1, but its expression is investigated as a cancer biomarker and putative intervention point.
- Other names
- MRNP41Mnrp41Gle2MIG14dJ481F12.3dJ800J21.1mRNA-associated protein mrnp 41mRNA export proteinmRNA-binding protein, 41-kDmigration-inducing gene 14rae1 protein homologhomolog of yeast Rae1mRNA-associated protein MRNP41
02
Mechanism of action
null (No clinical drugs; known viral protein inhibition: VSV matrix inhibits nuclear export by targeting Rae1-Nup98 complex[2])
03
Biological functions
mRNA nuclear export[nucleocytoplasmic transport][4][5][2][3]Mitotic checkpoint regulation and spindle formation[1][4][5][2]RNA binding and attachment of mRNPs to cytoskeleton[3][5][4]Regulation of epithelial-mesenchymal transition (EMT)[1]
04
Disease associations
Cancer (breast cancer: upregulation associated with aggressiveness and poor prognosis)[1]Chromosome instability syndromes/aneuploidy[1][5]Neurodevelopmental disorders (e.g., Lethal Congenital Contracture Syndrome, Anterior Horn Cell Disease)[5]Premature aging/early aging phenotype[1]
05
Safety considerations
Chromosome instability and aneuploidy risk with altered Rae1 expression[1]Early aging and neurodevelopmental defects with loss of function[1][5]Cancer progression/tumor aggressiveness if overexpressed[1]
06
Interacting drugs
null (No direct drugs documented; VSV matrix protein inhibits Rae1 function[2])
07
Biomarkers
RAE1 expression as a prognostic marker in breast cancer (correlates with disease-free survival and metastasis, especially in ER-positive tumors)[1]
Beyond the preview
Go deeper on mRNA export factor RAE1 (RAE1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA export factor RAE1 (RAE1).